Mineralys Therapeutics Inc (NASDAQ:MLYS)’s traded shares stood at 0.34 million during the last session, with the company’s beta value hitting 1.44. At the close of trading, the stock’s price was $9.81, to imply a decrease of -2.39% or -$0.24 in intraday trading. The MLYS share’s 52-week high remains $16.91, putting it -72.38% down since that peak but still an impressive 12.54% since price per share fell to its 52-week low of $8.58. The company has a valuation of $488.24M, with an average of 0.23 million shares in intraday trading volume over the past 10 days and average of 230.79K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Mineralys Therapeutics Inc (MLYS), translating to a mean rating of 1.00. Of 2 analyst(s) looking at the stock, 0 analyst(s) give MLYS a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy.
Mineralys Therapeutics Inc (NASDAQ:MLYS) trade information
After registering a -2.39% downside in the last session, Mineralys Therapeutics Inc (MLYS) has traded red over the past five days. The 5-day price performance for the stock is -4.76%, and -24.42% over 30 days. With these gigs, the year-to-date price performance is -20.31%. Short interest in Mineralys Therapeutics Inc (NASDAQ:MLYS) saw shorts transact 1.87 million shares and set a 7.47 days time to cover.
The extremes give us $30 and $30 for target low and target high price respectively. As such, MLYS has been trading -205.81% off suggested target high and -205.81% from its likely low.
MLYS Dividends
Mineralys Therapeutics Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Mineralys Therapeutics Inc (NASDAQ:MLYS)’s Major holders
Mineralys Therapeutics Inc insiders hold 2.52% of total outstanding shares, with institutional holders owning 102.40% of the shares at 105.05% float percentage. In total, 102.40% institutions holds shares in the company.
We also have iShares Russell 2000 ETF and American Century Small Cap Growth Fund as the top two Mutual Funds with the largest holdings of the Mineralys Therapeutics Inc (MLYS) shares. Going by data provided on Nov 30, 2024 , iShares Russell 2000 ETF holds roughly 807.86 shares. This is just over 1.62% of the total shares, with a market valuation of $7.93 million. Data from the same date shows that the other fund manager holds a little less at 793.8, or 1.59% of the shares, all valued at about 7.79 million.
